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A B S T R A C T   
Celiac disease (CD) is a systemic immune-mediated disorder with increased frequency in the developed countries 
over the last decades implicating the potential causal role of various environmental triggers in addition to gluten. 
Herein, we apply determination of perfluorinated alkyl substances (PFAS) and combine the results with the 
determination of bile acids (BAs) and molecular lipids, with the aim to elucidate the impact of prenatal exposure 
on risk of progression to CD in a prospective series of children prior the first exposure to gluten (at birth and at 3 
months of age). Here we analyzed PFAS, BAs and lipidomic profiles in 66 plasma samples at birth and at 3 
months of age in the Type 1 Diabetes Prediction and Prevention (DIPP) study (n  17 progressors to CD, n  16 
healthy controls, HCs). Plasma PFAS levels showed a significant inverse association with the age of CD diagnosis 
in infants who later progressed to the disease. Associations between BAs and triacylglycerols (TGs) showed 
different patterns already at birth in CD progressors, indicative of different absorption of lipids in these infants. In 
conclusion, PFAS exposure may modulate lipid and BA metabolism, and the impact is different in the infants who 
develop CD later in life, in comparison to HCs. The results indicate more efficient uptake of PFAS in such infants. 
Higher PFAS exposure during prenatal and early life may accelerate the progression to CD in the genetically 
predisposed children.  
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1. Introduction 
Celiac disease (CD) is a systemic immune-mediated disorder, which 
is triggered by gluten and other prolamins in genetically susceptible 
individuals (Caio et al., 2019). The frequency of CD has increased in the 
developed countries over the last decades, implicating the potential 
causal role of various environmental triggers in addition to gluten. 
Similarly to CD, the rate of other autoimmune diseases such as type 1 
diabetes (T1D) has also increased during the last decades (Assa et al., 
2017; Holmes and Muirhead, 2017). CD and T1D share common pre-
disposing alleles in the class II HLA-region (Ilonen et al., 2016; Sen et al., 
2019), and approximately 10% of patients with T1D also develop clin-
ical CD (Rewers et al., 2004; Scaramuzza et al., 2013), while subjects 
with CD are at-risk for developing T1D before 20 years of age (Lud-
vigsson et al., 2006). The possible triggers that have been indicated to 
affect the progression to CD include the composition of the intestinal 
microbiota, infant feeding, and the use of antibiotics (Caio et al., 2019; 
Kirchberg et al., 2016; Lionetti and Catassi, 2015). 
The hygiene hypothesis, stating that a decrease of the infectious 
burden is associated with the rise of allergic and autoimmune diseases, 
has also been proposed in CD because CD has shown to be more common 
in developed countries (Olen et al., 2012; Whyte et al., 2014; Zingone 
et al., 2015). Another possible explanation for varying incidence in 
different populations implicates the role of different infant feeding 
patterns (including the amount and timing of gluten introduction) in 
families with low socioeconomic status (Zingone et al., 2015). Socio-
economical status (SES) may also have a broader role in increasing the 
risk for CD, such as different exposures to environmental pollutants. 
Higher SOS has in several studies been linked to higher burdens of 
several persistent organic pollutants (POP), particularly to per-
fluorinated alkyl substances (PFAS) (Buekers et al., 2018; Tyrrell et al., 
2013). Exposure to POPs has, however, been poorly investigated as a 
risk factor for CD. In T1D, recent studies identified associations between 
the exposures to environmental chemicals and the increased risk of islet 
autoimmunity (Conway et al., 2016; Nistico et al., 2012; Predieri et al., 
2015; Stene and Gale, 2013). We have shown that fetal exposure to PFAS 
increases the risk of T1D in genetically susceptible individuals 
(McGlinchey et al., 2019), and further, that the metabolic profiles of the 
infants are affected by the prenatal exposure to PFAS. In particular, the 
PFAS exposure has a marked impact on bile acid (BA) profiles, which, in 
turn, were linked to changes in specific phospholipids, e.g., lysophos-
phatodylcholines (LPCs), phosphatodylcholines (PCs) and sphingo-
myelins (SMs). Similarly, we have recently identified systematic 
differences in plasma lipid profiles between children who later pro-
gressed to clinical CD during the follow-up, when compared to children 
who remained healthy (Sen et al., 2019). Importantly, these differences 
were observed prior to the first introduction of gluten in the diet and 
before the first signs of CD-associated autoimmunity. Similar results 
were recently reported in an Italian cohort study (Auricchio et al., 
2019). 
In line with the observations of intestinal dysbiosis in CD (Caio et al., 
2019), changes in lipid metabolism (Auricchio et al., 2019; Sen et al., 
2019) as well as the documented link of CD with liver disorders 
(Hoffmanova et al., 2018), it has been shown that circulating BAs are 
elevated in CD, including in children (Ejderhamn et al., 1992; Vuoristo 
and Miettinen, 1987). BAs not only facilitate the digestion and absorp-
tion of dietary lipids in the small intestine, they are also important 
metabolic regulators involved in the maintenance of lipid and glucose 
homeostasis (Chiang, 2017). BAs are produced in the liver, and their 
homeostasis is maintained through the tightly controlled enterohepatic 
circulation. Moreover, there is a close interplay between BA and gut 
microbiota. Gut microbiota is involved in the biotransformation of 
secondary BAs, while BAs can modulate the microbial composition in 
the gut due to their antimicrobial activity as well as through regulation 
of the composition of the intestinal microbiota through farnesoid X re-
ceptor (FXR) and Takeda G-protein receptor 5 (TGR-5) (Barrasa et al., 
2013; Ramírez-Perez et al., 2017). PFAS, on the other hand, have been 
shown to undergo similar enterohepatic circulation as the BAs, and PFAS 
can also suppress the BA biosynthesis in the liver (Zhao et al., 2015). 
Here we hypothesized that early life PFAS exposure affects the BA 
profiles in children and explains the association between the early 
changes in lipid profiles in those children who later progress to clinical 
CD. We investigated the impact of early-life exposure to PFAS in chil-
dren who progressed to clinical CD during their follow-up, and 
compared the exposures to those observed in children who remained 
healthy during the follow-up. In addition, we also analyzed BAs in the 
same samples, and performed integrative analysis of previously pub-
lished lipidomic profiles (Sen et al., 2019), together with PFAS and BA 
levels. 
2. Materials and methods 
2.1. Study design 
The current study is a part of the Type 1 Diabetes Prediction and 
Prevention study in Finland (DIPP), which is an ongoing prospective 
birth cohort study initiated in 1994. In DIPP, parents of newborn chil-
dren at the university hospitals of Turku, Tampere and Oulu in Finland 
are asked for permission to screening for T1D-conferring HLA risk alleles 
in the umbilical cord blood. Families of children identified as having an 
increased HLA-conferred risk for T1D were invited to join the follow-up 
study. This study included children born in Tampere University Hospital 
between August 1999 and September 2005. During that period, 23,839 
children were screened at birth for increased risk of T1D, and 2642 
eligible children were enrolled in the follow-up and had at least two 
visits to the study center. These children carry the high-risk HLA 
DQB1*02/*03:02 genotype or the moderate-risk HLA-DQB1*03:02/x 
genotype (x 6 DQB1*02, 03:01, or 06:02). More than 1200 of these 
children took part in the DIPP-CD study. Because of the enrolment 
criteria 60% of the children were male. At each visit, the families were 
interviewed for dietary changes, infections, growth, important family 
related issues and the children gave a non-fasting venous blood sample. 
The children were followed for four CD-related antibodies: anti- 
transglutaminase 2 (anti-TG2), anti-endomysium (EMA), antigliadin 
(AgA-IgG and AgA-IgA) and anti-reticulin (ARA) antibodies, and for four 
T1D-associated autoantibodies: islet cell autoantibodies (ICA), autoan-
tibodies against insulin (IAA), tyrosine phosphatase-like protein (IA-2A) 
and glutamate decarboxylase (GADA). IgA deficiency was excluded. All 
children participating in this study were of Caucasian origin. None of the 
mothers had CD. The children in the CD follow-up cohort were annually 
screened for anti-TG2 antibodies using a commercial kit (Celikey 
Pharmacia Diagnostics, Freiburg, Germany). If a child’s sample was 
found positive, all previous and forthcoming samples were analyzed for 
the entire set of CD-related antibodies. A duodenal biopsy was recom-
mended for all anti-TG2-positive children. If the biopsy was consistent 
with the ESPGHAN criteria of 1990, a gluten-free diet (GFD) was rec-
ommended. None of the children participating in this study had any 
T1D-associated autoantibodies in any samples during the follow-up. The 
first exposure to gluten in this study was at the median age of 5 months 
(Table 1). 
We have randomly selected 17 children with biopsy proven CD 
(progressors) and a matched control for each progressor, carrying 
similar risk HLA alleles, born within 1 month of each other, having had 
each sample taken within 1 month of each other and living in the same 
region of the country throughout the whole follow-up period. Samples at 
birth (cord blood) and at 3 months of age were analyzed. Altogether, 76 
plasma samples from children developing CD and from their HCs were 
analyzed. The clinical and genetic data of the participants are found in 
Table 1. 
The ethics committee of the Tampere University Hospital approved 
the study. Written informed consent was obtained from the parents for 
HLA-screening, autoantibody analysis and intestinal biopsies. 
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2.2. Analysis of PFAS and BAs 
The BAs and PFAS were analyzed using the established method as 
described previously (Salihovic et al., 2020). In brief, the sample prep-
aration was done with 25 mg Ostro Protein Precipitation and Phos-
pholipid Removal 96-well plate (Waters Corporation, Milford, USA), 
using 30 μL of serum and a set of BA and PFAS internal standards. 
Matrix-matched calibration standards were made using newborn bovine 
serum. Analyses were performed on an Acquity UPLC system coupled to 
a triple quadrupole mass spectrometer (Xevo TQ-S, Waters Corporation, 
Milford, USA) with an atmospheric electrospray interface operating in 
negative ion mode. Aliquots of 10 μL of samples were injected into the 
Acquity UPLC BEH C18 2.1 mm  100 mm, 1.7 μm column (Waters 
Corporation). A trap column (PFC Isolator column, Waters Corporation) 
was installed between the pump and injector and used to retain fluori-
nated compounds originating from the HPLC system and the mobile 
phase. The eluent system consisted of (A) 2 mM NH4Ac in 70% MiliQ: 
30% methanol and (B) 2 mM NH4Ac in 100% methanol. The gradient 
was programmed as follows: 0–1 min, 1% solvent B; 1–13 min, 100% 
solvent B; 13–16 min, 100% solvent B; 16–17 min, 1% solvent B, flow 
rate 0.3 mL/min. The total run time for UPLC-MS/MS analysis was 17 
min, while the total run time for each sample injection was 20 min, 
including the reconditioning of the analytical column. MS analysis was 
performed in multiple reaction monitoring (MRM) mode and experi-
mental details of the MS/MS method are given in Supplemental Table 1. 
2.3. Lipidomic analyses 
The lipidomic analyses were performed as described previously (Sen 
et al., 2019). The plasma samples (10 μL) were extracted using a 
modified version of the previously published Folch procedure (Folch 
et al., 1957). The samples were analyzed using an 
ultra-high-performance liquid chromatography quadrupole 
time-of-flight mass spectrometry method (UHPLC-Q-TOF-MS from Agi-
lent Technologies (Santa Clara, CA, USA). The analysis was carried out 
on an ACQUITY UPLC® BEH C18 column (2.1 mm  100 mm, particle 
size 1.7 μm) by Waters (Milford, USA). Internal standard mixture was 
used for normalization and lipid-class specific calibration was used for 
quantitation as previously described. Quality control was performed 
throughout the dataset by including blanks, pure standard samples, 
extracted standard samples and control plasma samples. Relative stan-
dard deviations (%RSDs) for lipid standards representing each lipid class 
in the control plasma samples (n  8) and in the pooled serum samples 
(n  20) were on average 11.7% (raw variation). The RSD% for lipid 
concentrations in the pooled control samples was on average 8.4% and 
11.4% in the standard samples. This shows that the method is reliable 
and repeatable throughout the sample set. MS data processing was 
performed using open source software MZmine 2.18 (Pluskal et al., 
2010). 
2.4. Statistical analyses 
Statistical analysis was performed using R (v3.6.0) statistical pro-
gramming language (R Development Core Team, 2018). Previously 
published lipidomics dataset (Sen et al., 2019) was obtained from 
MetaboLights with the study identifier MTBLS729. The data was 
log-transformed and missing values were imputed by half of the row’s 
minimum. The datasets were auto-scaled prior to multivariate analyses. 
To integrate across different data types, we applied sparse general-
ized correlation discriminant analysis via the DIABLO framework, part 
of mixOmics package (v6.10.8) (Rohart et al., 2017). The method con-
structs components across different data blocks, by maximizing their 
covariance with each other and a given response (Y) variable. Heter-
ogenous data such as PFAS, BAs and lipid levels were partitioned into 
three different blocks and regressed to a binary response variable, i.e., 
CD progressors (CD) or HCs. Regularized sparse partial least squares 
discriminant (sPLS-DA) (Le Cao et al., 2011; Rohart et al., 2017) models 
were fitted. The optimal number of components that achieve the best 
performance based on the overall error rate or Balanced Error Rate 
(BER) were determined. Block sPLSDA models were developed at two 
time-points, i.e., at birth (cord blood) and at 3 months of age. Moreover, 
these models were cross-validated (Westerhuis et al., 2008) by 5-fold 
cross-validation (CV) with (N  100 repeats). The final model perfor-
mances were assessed by area under the curve (AUC), overall misclas-
sification error rate, and BER generated using ‘perf’,’auroc’,’block.splsda’ 
functions. 
The key predictors/contributors that are jointly associated with the 
response variable of interest across all the input data matrices were 
identified by their Variable Importance (VI) score, i. e (absolute weighted 
loadings). The direction (up or down) of contribution of a particular 
predictor was determined by estimating the mean relative log fold 
change in the CD progressors vs. HCs at a particular time-point. 
In order to understand which variables influence the outcomes, 
multivariate correlations were performed by a method described in 
(Rohart et al., 2017). In addition, bivariate correlation was performed 
using Pearson correlation. Debiased Sparse Partial Correlation algorithm 
(DSPC) was used for estimating partial correlation networks, visualized 
by the MetaboAnalyst 4 (Chong et al., 2019) version with cutoff values of 
correlations between  0.22 to 0.75. Univariate analysis (unpaired two 
sample t-test and paired t-test) using the ‘t.test’ function, was deployed to 
identify mean differences in the concentration of individual PFAS and 
BAs between CD progressors vs. HCs at birth and at 3 months of age. 
Libraries/packages such as ‘Heatmap.2’, ’mixOmics’, ‘boxplot’, ‘beanplot’, 
‘gplot’ and ‘ggplot 2’ were used for data visualization. 
Generalized Linear regression was performed and coefficient of 
determination (R2) was estimated using glm () function from stats 
v3.6.2 R package. Pearson correlation analysis was performed using cor. 
test () function encoded in the stats package. 
3. Results 
3.1. Levels of PFAS and BAs in the infants 
Seven PFAS compounds were detected in the samples, namely 
PFHpA, PFHxS, PFOA, PFNA, PFOS, PFDA and PFUnDA, both at birth 
and at 3 months of age (Supplemental Table 2). PFOS and PFOA had the 
highest concentrations and they were detected in the majority of sam-
ples, whilst PFDA and PFNA were detected in less than 10% of the 
samples and were excluded from further analyses. The levels of PFAS 
were lower in the cord blood (CB) than at the age of 3 months 
(Fig. 1A–C). No significant differences were observed between cases and 
controls either at birth or at 3 months of age (Fig. 1A–C). Interestingly, 
the levels of the total PFAS were significantly elevated from birth to 3 
months of age only in the CD group (fold change (FC) 3 months vs. at 
birth  1.72, p  0.003, Supplemental Table 3) although also controls 
had an increasing trend (FC  1.02, p  0.35). Among the individual 
Table 1 
Demographic and clinical characteristics of the study subjects.   
Celiac Disease Healthy Controls 
Number of subjects 17 16 
Gender 
Male (median) 10 8 
Female (median) 7 8 
Age of first gluten intake (median) 5.25 months 5.3 months 
Age of first tTGA (median) (seroconversion) 58 months – 
First tTGA level in plasma (median EIU) 116.8 – 
Endoscopy Age (median) 58.5 months – 
tTGA level after GFD (median EIU) 7.1 – 
Total follow-up age from birth (median) 6.08 years 6.2 years  
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PFAS, PFOA showed nearly twofold increase, being significant in both 
groups (Fig. 1A–C) (Supplemental Table 3). 
In addition to the two primary BAs, we measured five primary/ 
conjugated and secondary BAs (Supplemental Table 2). The levels of 
secondary BAs were mostly below the detection limits, particularly in 
the cord blood samples, where the total BA pool consisted mainly of GCA 
Fig. 1. Bean plots showing distribution of selected PFAS and BAs in CD progressors and HCs. A-C) Levels (log2 intensities) of selected PFAS in cord blood (0 Mo) and 
at 3 months (3 Mo) of age in the CD progressors (CD) and HCs. D-F) Levels (log2 intensities) of selected BAs in the cord blood and at 3 months of age. The red dotted 
line denotes the mean of the population. The black solid lines in the bean plots represent the group mean. The group mean difference between case-control at a 
particular time-point was tested by unpaired two-sample t-test. Mean difference between cord blood and 3 months samples obtain from the same infants were tested 
by paired t-test. CD, HCs and BA denotes CD progressors, healthy controls and bile acids respectively. (For interpretation of the references to color in this figure 
legend, the reader is referred to the Web version of this article.) 
Fig. 2. Molecular network of PFAS (yellow color), BAs (green color), lipid classes (blue color), and clinical variables (orange color) measured in the cord blood: A) 
Healthy controls. B) CD progressors. Red and blue lines denote positive and negative correlations respectively. The width of the lines represents the strength of 
correlation. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.) 
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and GCDCA. Similarly, as for PFAS, no significant differences were 
observed between cases and controls either at birth or at 3 months of age 
(Fig. 1D–F). The BA profiles at birth and at 3 months of age were 
markedly different in both groups (Fig. 1D–F). The total BA pool showed 
significant, almost sevenfold upregulation (p  0.0001). Particularly, 
GHCA and CDCA, which were close the limits of detection at birth, have 
increased substantially with age. 
3.2. Associations between PFAS, BA and lipid levels 
Partial correlation network analysis between PFAS, BAs and lipids 
(classes) measured in cord blood showed a different pattern of associa-
tion in HCs (Fig. 2A) and CD progressors (Fig. 2B). In the HCs, the level 
of deoxycholic acid (DCA) was inversely asociated with the sex of the 
infant, whereas no such association was seen in the CD progressors. 
Interestingly, DCA concentration was inversely associated with the level 
of PFOA. The CD group showed a strong association between age at 
diagnosis and PFOA exposure at both time points (Fig. 2B, Supplemental 
Fig. 1). In general, there was direct association between PFAS and 
several lipid classes. Age at diagnosis was also inversely associated with 
total TGs at birth. The association showed a clearly different pattern in 
the controls, both at birth and at the later time point (Fig. 2). 
To understand how the individual PFAS and BAs are associated with 
the molecular lipid species, we performed multivariate (Rohart et al., 
2017) and bivariate correlation analysis. Bivariate correlation analysis 
identified different correlation patterns in HCs and in CD progressors 
(Fig. 3). In the control group there were significant associations mainly 
between the levels of the lipid classes at birth, and only the total con-
centrations of TGs showed associations with BAs (Fig. 3A). In the CD 
progressor group, we observed significant correlations between the 
levels of BAs (GUDCA, GHCA, CDCA) and with multiple lipid classes in 
cord blood (PE, TG, SM) (Fig. 3B). At 3 months of age, the patterns were 
different from those seen at birth. In the control group, specific BAs 
(CDCA, GUDCA, TCDCA and GCHA) showed a significant association 
Fig. 3. Correlation plots of PFAS, BA and lipid classes in (A) Controls at birth, (B) CD at birth, (C) controls at 3 months and (D) CD at three months. Red and blue 
colors denote positive and negative correlations respectively. Significant Pearson correlations are marked with *. (For interpretation of the references to color in this 
figure legend, the reader is referred to the Web version of this article.) 
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with lipid levels, mainly with cholesterol esters (CEs) and TGs, with 
variable patterns depending on the fatty acyl saturation level (Fig. 3C). 
Only a weak correlation was observed between the levels of PFAS and 
LPCs, while overall the PFAS levels were not associated with either lipids 
or BAs. In CD progressors, the patterns were different from the controls 
also at 3 months of age (Fig. 3D). In this group, PFAS (PFOS and 
PFUnDA) levels and concentrations of TGs showed significant correla-
tions, particularly with TGs containing saturated FAs. In addition, con-
centrations of BAs were also associated with those of TGs (DCA, GCA, 
CDCA and TCDA, total BAs), the directions being dependent on the bile 
acid species. 
The main difference between the groups was the absence of corre-
lation between the LPCs and the other phospholipid classes (PC, SM, PE) 
in CD progressors, while there was a strong and significant co-regulation 
of these lipid classes in the control group. At birth, there were no 
significantly different individual lipids between the groups (Sen et al., 
2019), however, the LPCs showed overall increased levels and most of 
the PCs decreased levels. LPC/PC ratio, with selected PC species con-
taining PUFAs, showed significant upregulation in the CD group (FC 
1.3, p  0.01). 
3.3. Molecular predictors of PFAS, BA and lipids in CD progression 
Multivariate correlation analysis showed strong associations (r >
0.8) among PFAS, BAs and molecular lipids such as cholesterol esters 
(CEs), lysophosphatidylcholines (LPCs), phosphatidylcholines (PCs), 
phosphatidylethanolamines (PEs), sphingomyelin (SMs) and tri-
acylglycerols (TGs) (Fig. 4A). These associations become more complex 
at 3 months of age (Fig. 4D). 
Next, we selected those lipids that showed significant differences 
between CD and HCs in infancy in our previously reported study (Sen 
et al., 2019). These lipids together with the BAs and PFAS were sub-
jected to multiblock (MB) analysis. MB analysis identified PFAS, BA and 
molecular lipid species as predictors (discriminative features) that hel-
ped to classify CD progression vs. HCs. The association between top 
predictors (high variable importance scores) are shown (Fig. 4 A, D). 
In cord blood, the levels of PFOA and PFOS were identified as the top 
linear predictors of CD progression (Fig. 4B). On the other hand, among 
the BAs, the levels of primary BAs such as GCA and GHCA are the 
strongest predictors of CD progression (Fig. 3C). Moreover, elevated 
concentration of PFOA in the CD progressors was positively associated 
with the levels of GCA and GHCA. This suggests that prenatal exposure 
to PFOA and/or PFOS might accelerate the risk of CD progression. 
Presumably, it alters the BA and lipid metabolism. Interestingly, lipids 
such as CE (18:1) (intermediate of BA synthesis) were identified as 
predictors of CD progression; the levels of PFOA and PFOS were 
inversely correlated with those of CEs (Figs. 4A and 5A). In addition, 
many ether-linked PCs such as PC(O-34:3), PC(O-36:3,4) and PC(O- 
38:4,5,6) were identified as key contributors, that were down-
regulated in the CD progressors as compared to the HCs (Figs. 4A and 
Fig. 4. Integrative multiblock component analysis of PFAS, BAs and molecular lipids in the CD progressors vs. HCs. A, D) Circos plots (2 principal components) 
showing overall association (full-design matrix) between covariates of PFAS, BAs and molecular lipids in cord blood (CB), and at 3 months of age. Red and blue line 
denotes positive and negative correlations respectively. Sparse generalized correlation (Rohart et al., 2017) (coefficient, r > 0.5) are shown. B–C) Horizontal barplots 
showing top selected predictors/contributors/discriminators from each PFAS and BA data blocks, where the length of bar corresponds to the absolute loading weights 
(variable importance) of the feature, that tends to discriminate CD progressors vs. HCs at birth. The direction of regulation of the predictors are shown with light 
brown and blue colors that corresponds to the CD progressors or HCs respectively; wherever the mean intensity of the predictor is maximum. E-F) Key predictors of 
PFAS and BAs, that helped to classify CD progressors vs. HCs at 3 months (3 Mo) of age. The model performance on each block of data are given by cumulative 
(principal components) area under the curves (AUCs). (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of 
this article.) 
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5A). 
At 3 months of age, concentrations of PFHxS was marked as a top 
predictor associated with CD progression, along with levels of PFOA and 
PFOS. Moreover, the level of PFHxS were increase in the CD progressors 
as compared to HCs (Figs. 1A, 4E and 5B). At this age, elevated levels of 
secondary BAs such as DCA and CDCA were marked as the key pre-
dictors for CD progression (Fig. 4F). As stated before, the level of PFOA 
was inversely correlated with that of DCA (Fig. 2B), suggesting an 
interaction between the PFAS and BAs in the CD progressors. Moreover, 
PFOA was inversely linked to age at diagnosis of CD (Figs. 2B and 6). In 
addition, the MB model identified several PCs, SM(d36:2), PC(O-38:4,5) 
as key predictors that discriminate the lipid profiles of CD progressors 
from those seen in the HCs (Fig. 5B). 
4. Discussion 
We observed dysregulation between intralipid class regulation at 
birth in those infants that progressed to CD, particularly in LPC/PC ra-
tios. PFOS and PFHxS levels were also positively associated with LPCs in 
the CD progressors, but not in HCs. However, 3 months later, the ratio 
was similar in both groups. Increased LPCs have been indicated to be 
characteristic for CD progression at later time points, both our earlier 
study as well as in another recent study showed increased LPCs already 
in those 4-month-old infants who progressed later to CD (Auricchio 
et al., 2019). Furthermore, our results implied that the associations 
between BAs and complex lipids show different patterns already at birth 
in those infants who later developed CD as compared with healthy 
controls. Significant correlations were observed between TGs and spe-
cific BAs already at birth in the CD progressors. At 3 months of age, both 
groups showed a significant correlation between the lipids and BAs, 
although the patterns were different. At this later time point, the CD 
group showed significant positive correlations between different classes 
of TGs while the healthy controls showed inverse correlations. Thus, the 
data agrees well with our earlier study, in which we observed distinct 
lipid changes, particularly in the TG class, in children who later pro-
gressed to CD already prior to the first exposure to dietary gluten. The 
data suggested that the specific TGs, found elevated in the CD pro-
gressors, may be due to a host response to compromised intake of 
essential lipids in the small intestine, requiring de novo lipogenesis. The 
current study suggests that the changes in TG metabolism are also 
related to alteration in BA metabolism, and that early-life exposure to 
PFAS may contribute to these changes. Currently, there is very limited 
amount of data on BA and lipid metabolism in infants. The BA pool in the 
fetus and in newborn infants is unique. More than 90% of fetal BAs 
represent conjugated forms of the primary BAs, cholic acid (CA) and 
chenodeoxycholic acid (CDCA), since the intestinal bacteria necessary to 
transform primary BAs into secondary BAs are thought to be absent in 
utero, Based on recent findings, the fetal BAs may be very different than 
later in life (Jebbink et al., 2015; Seki et al., 2011). The enterohepatic 
circulation of BAs in utero is also minimal. Instead, there is a trans-
placental gradient for BAs in the fetal-to-mother direction, except for 
secondary and tertiary BAs, which are more abundant in maternal serum 
(Macias et al., 2009). 
PFAS exposure has been shown to impact BA metabolism through 
several mechanisms. BAs and PFAS have been shown to have a similar 
enterohepatic circulation (Chiang, 2017; Zhao et al., 2015), and it has 
been indicated that 7-alpha-hydroxylase (CYP7A1), which catalyzes the 
first and rate-limiting step in the classical pathway in the formation of 
BAs from cholesterol, may be down-regulated by PFAS (Beggs et al., 
2016; Chiang, 2017). This might lead to increased re-uptake of BAs, 
which would generate negative feedback loops via the 
farnesyl-X-receptor and subsequently reduce their de novo synthesis 
(Chiang, 2017; Pandak and Kakiyama, 2019). It has also been shown 
that PFOA inhibits the function of the hepatocyte nuclear factor 4α 
Fig. 5. Key lipid contributors/predictors, that jointly (together with PFAS and BAs), aided in the separation of CD progressors vs. HCs, at birth and at 3 months of age. 
The direction of regulation of the predictors are shown with light brown and blue colors that corresponds to the CD progressors or HCs respectively; wherever the 
mean intensity of the predictor is maximum. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of 
this article.) 
L. Sinisalu et al.                                                                                                                                                                                                                                 
Environmental Research 188 (2020) 109864
8
(Buhrke et al., 2015), which plays a central role in the regulation of BA 
metabolism in the liver, and is linked both with the synthesis and 
conjugation of primary BAs. However, in neonates, the alternative 
(acidic) pathway is the major pathway for bile acid synthesis and this 
pathway is governed by mitochondrial sterol 27-hydroxylase 
(CYP27A1), which can initiate a process independent of CYP7A1. Only 
after weaning, CYP7A1 is expressed and the classic pathway becomes 
the major pathway for bile acid synthesis in the liver (Chiang, 2017). 
There is currently no data on the impact of PFAS exposure on the 
regulation of the CYP27A1. On the other hand, the impact of PFAS on 
the TG metabolism may be modulated through the bile acids, as the bile 
acid receptor FXR has also a regulatory role in triglyceride metabolism 
(Behr et al., 2020; Bjork et al., 2011; Zhang et al., 2015). In humans, 
recent data suggests that FXR is not activated directly by PFAS (Behr 
et al., 2020). In the liver, FXR activation, by, e.g., bile acids, would result 
in downregulation of CYP7A1, which in addition to inhibition of the 
classical BA synthetic pathway also reduces the expression of several 
genes mediating free fatty acid synthesis, thereby attenuating de novo 
lipogenesis (Chiang, 2017). Thus, activation of FXR modulates free FA 
oxidation and the clearance of TG to the circulation. 
The acylalkyl PCs type of lipids that showed significant association 
with the CD progression were positively associated with the levels of 
total BAs and PFHxS, indicating potentially disturbed hepatic synthesis 
of these lipids, particularly as the intra-lipid regulation between these 
lipids and particularly TGs was disturbed in CD progressors. These ether 
lipids are perceived to function as endogenous antioxidants in addition 
to their structural roles in cell membranes, and emerging studies suggest 
that they are involved in cell differentiation and signaling pathways as 
well (Dean and Lodhi, 2018). Interestingly, these lipids have been 
observed to be endogenous antigens to activate invariant natural killer T 
cells (iNKT) (Facciotti et al., 2012), which are subset of innate immune 
cells. Recently, therapeutic potential of iNKT cell antigens against 
autoimmunity has been identified (Van Kaer and Wu, 2018). Thus, the 
reduced levels of the alkyl ether lipids could suggest a compromised 
response to oxidative stress. Interestingly, these lipids have previously 
been found to be associated with disease development also in other 
autoimmune diseases, such as type 1 diabetes (Oresic et al., 2013), thus 
indicating that they may play an important role in the development of 
autoimmune disorders. Due to their role in cell membranes, the decrease 
in ether-linked PCs particularly, PC(O-38:4,5) might also attribute to 
compromised intestinal permeability in the CD progressors. 
Taken together, our results show that PFAS exposure may modulate 
lipid and BA metabolism, and the impact is different in the infants who 
develop CD later in life, when compared with healthy controls. Although 
we did not observe any significant differences in the levels of PFAS 
exposure in those children that later developed CD, which may be due to 
the small sample size, we did observe a significant increase in their levels 
in progressors to CD from the time of birth to 3 months of age, suggesting 
more efficient uptake of PFAS. Furthermore, age at diagnosis of CD was 
strongly associated with the PFAS exposure. Our study thus suggests that 
further investigations of the impact of exposures to environmental 
chemicals in the development of autoimmune diseases are merited. 
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